Building bone to reverse osteoporosis and repair fractures.
An important, unfilled clinical need is the development of new approaches to improve fracture healing and to treat osteoporosis by increasing bone mass. Recombinant forms of bone morphogenetic protein 2 (BMP2) and BMP7 are FDA approved to promote spinal fusion and fracture healing, respectively, and the first FDA-approved anabolic drug for osteoporosis, parathyroid hormone, increases bone mass when administered intermittently but can only be given to patients in the US for two years. As we discuss here, the tremendous explosion over the last two decades in our fundamental understanding of the mechanisms of bone remodeling has led to the prospect of mechanism-based anabolic therapies for bone disorders.
Khosla
Sundeep
S
Endocrine Research Unit, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Westendorf
Jennifer J
JJ
Oursler
Merry Jo
MJ
D045930:Anabolic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016723:Bone Remodeling / Q000187:drug effects*; D002454:Cell Differentiation; D015195:Drug Design; D050723:Fractures, Bone / Q000188:drug therapy*; D006801:Humans; D010006:Osteoblasts / Q000187:drug effects*; D010011:Osteocytes / Q000187:drug effects; D010012:Osteogenesis / Q000187:drug effects*; D010024:Osteoporosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000494:pharmacology / Q000627:therapeutic use
D045930:Anabolic Agents; D010281:Parathyroid Hormone